Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies-Reference-Cited by-同舟云学术

Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies

Published:2021-05-27 Issue:5 Volume:149 Page:1189-1198
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Gorgulho Joao¹²^ORCID,Roderburg Christoph³,Heymann Felix⁴,Schulze‐Hagen Maximilian⁵,Beier Fabian⁶,Vucur Mihael³,Kather Jakob N.⁷,Laleh Narmin Ghaffari⁷,Tacke Frank⁴,Brümmendorf Tim H.⁶,Luedde Tom³,Loosen Sven H.³^ORCID

Affiliation:

1. Division of Gastroenterology, Hepatology and Hepatobiliary Oncology University Hospital RWTH Aachen Aachen Germany

2. Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology University Medical Centre Hamburg‐Eppendorf Hamburg Germany

3. Clinic for Gastroenterology, Hepatology and Infectious Diseases University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf Düsseldorf Germany

4. Department of Hepatology and Gastroenterology Charité University Medicine Berlin Berlin Germany

5. Department of Diagnostic and Interventional Radiology University Hospital RWTH Aachen Aachen Germany

6. Department of Medicine IV University Hospital RWTH Aachen Aachen Germany

7. Department of Medicine III University Hospital RWTH Aachen Aachen Germany

Funder

Deutsche Krebshilfe

H2020 European Research Council

Publisher

Wiley

Subject

Cancer Research,Oncology

Link